Dronedarone
- TRADE NAME: Multaq (Sanofi-Aventis)
- INDICATIONS: Atrial fibrillation and atrial flutter
- CLASS: Antiarrhythmic, Antiarrhythmic class III
- HALF-LIFE: 13–19 hours
Amiodarone, Amitriptyline, Amoxapine, Antiarrhythmics, Antipsychotics prolonging QT interval, Arsenic, Atorvastatin, Beta blockers, Bupivacaine, Calcium channel blockers, Carbamazepine, Citalopram, Clarithromycin, Conivaptan, Coumarins, Cyclosporine, CYP3A inducers, Dabigatran, Darunavir, Dasatinib, Degarelix, Delavirdine, Digoxin, Diltiazem, Disopyramide, Dolasetron, Efavirenz, Erythromycin, Fingolimod, Grapefruit Juice, Indinavir, Itraconazole, Ketoconazole, Lapatinib, Levobupivacaine, Levofloxacin, Levomepromazine, Metoprolol, Moxifloxacin, Nefazodone, Neratinib, Nifedipine, Ombitasvir/Paritaprevir/Ritonavir, Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir, Oxcarbazepine, Pazopanib, Phenindione, Phenobarbital, Phenothiazines, Phenytoin, Posaconazole, Prilocaine, Propranolol, Rifampin, Rifapentine, Ritonavir, Ropivacaine, Rosuvastatin, Saquinavir, Simvastatin, Sirolimus, Sotalol, St John's Wort, Statins, Tacrolimus, Telavancin, Telithromycin, Tricyclic antidepressants, Venetoclax, Verapamil, Voriconazole, Vorinostat, Warfarin, Ziprasidone
PREGNANCY CATEGORY: X
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of dronedarone in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/31/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
